$2.19
0.052.34%
Pre-Market: 8:53 AM EDT
Comments
Loading...
Minerva Neurosciences (NERV) Forecast
NewsEarningsMinerva Neurosciences (NERV) OptionsGuidanceDividendsAnalyst RatingsInsider TradesShort InterestMinerva Neurosciences (NASDAQ:NERV) Stock Quotes, Forecast and News Summary
Minerva Neurosciences Stock (NASDAQ: NERV) stock price, news, charts, stock research, profile.
Compare
EPS better than industry
Earnings Per Share
EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.
Earnings Per Share
EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.
EPS better than industry
FAQ
How do I buy Minerva Neurosciences (NERV) stock?
You can purchase shares of Minerva Neurosciences (NASDAQ:NERV) through any online brokerage.
Who are Minerva Neurosciences (NERV) competitors?
Other companies in Minerva Neurosciences’s space includes: Eterna Therapeutics (NASDAQ:ERNA), Immuron (NASDAQ:IMRN), Acurx Pharmaceuticals (NASDAQ:ACXP), Imunon (NASDAQ:IMNN) and Sensei Biotherapeutics (NASDAQ:SNSE).
What is the forecast, or price target, for Minerva Neurosciences (NERV) stock?
Minerva Neurosciences has a consensus price target of $5.00.
What is the current price for Minerva Neurosciences (NERV)?
The stock price for Minerva Neurosciences (NASDAQ: NERV) is $2.19 last updated December 19, 2024 at 8:53 AM EST.
Does Minerva Neurosciences (NERV) pay a dividend?
There are no upcoming dividends for Minerva Neurosciences.
When is Minerva Neurosciences (NASDAQ:NERV) reporting earnings?
Minerva Neurosciences’s Q4 earnings are confirmed for Thursday, February 20, 2025.
Is Minerva Neurosciences (NERV) going to split?
There is no upcoming split for Minerva Neurosciences.
What sector and industry does Minerva Neurosciences (NERV) operate in?
Minerva Neurosciences is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.